Loading
Loading
Research Overview
Octapeptide analogue of Acetyl Hexapeptide-3 (Argireline); inhibits the SNARE complex at the neuromuscular junction to reduce acetylcholine release, decreasing muscle micro-contractions and expression wrinkles.
Snap-8, also known as Acetyl Octapeptide-3, is a synthetic peptide that has been explored in preclinical research for its potential role in modulating neurotransmitter release and neuromuscular signaling. Structurally derived as an analog of SNAP-25—a protein involved in synaptic vesicle fusion—Snap-8 consists of a short amino acid sequence engineered to mimic specific regulatory functions within cellular communication pathways. Unlike endogenous peptides, Snap-8 is fully synthetic and designed for targeted investigation under controlled laboratory conditions.
Across in vitro and experimental models, Snap-8 has been examined for its potential interaction with the SNARE complex, a group of proteins responsible for facilitating neurotransmitter release at synaptic junctions. Research has focused on how Snap-8 may influence signaling pathways associated with acetylcholine release, which plays a key role in muscle contraction and cellular communication. These studies often investigate receptor activity, vesicle docking mechanisms, and the broader regulatory systems involved in neuromuscular transmission.
In addition to its relevance in neurotransmission studies, Snap-8 has been evaluated in experimental settings for its potential effects on cellular signaling dynamics and peptide-protein interactions. Some findings suggest that it may alter the efficiency of synaptic transmission by interfering with protein complexes involved in exocytosis, offering insight into how peptide analogs may influence communication between cells.
To support consistent research outcomes, Snap-8 is synthesized with a focus on stability and reproducibility, enabling detailed observation across controlled experimental environments. All findings referenced are derived exclusively from non-clinical studies. There are no established conclusions regarding human safety, pharmacokinetics, dosing, or therapeutic applications, and all observations remain within the scope of ongoing scientific investigation.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, snap-8 peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Snap-8 Peptide research is most relevant to protocols examining:
Cosmetic peptide research targeting expression-line reduction
SNARE complex and neuromuscular junction biology studies
Topical anti-ageing formulation development research
Comparative studies versus Argireline/Acetyl Hexapeptide-3
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: N/A (topical)). Review data, confirm baseline recovery before any repeat protocol.
Octapeptide analogue of Acetyl Hexapeptide-3 (Argireline); inhibits the SNARE complex at the neuromuscular junction to reduce acetylcholine release, decreasing muscle micro-contractions and expression wrinkles.
| Parameter | Value |
|---|---|
| Dose range | Topical formulation (typically 4–10% in cream) |
| Schedule | 1–2× daily |
| Route | Topical |
| Half-life | N/A (topical) |
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
